Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery

We have determined whether an adenovirus that comprises the tail and shaft domains of a serotype 5 virus and the knob domain of a serotype 3 virus expressing MDA-7/IL-24, Ad.5/3-mda-7, more effectively infects and kills renal carcinoma cells (RCCs) compared to a serotype 5 virus, Ad.5-mda-7. RCCs are a tumor cell type that generally does not express the receptor for the type 5 adenovirus; the coxsakie and adenovirus receptor (CAR). Ad.5/3-mda-7 infected RCCs to a much greater degree than Ad.5-mda-7. MDA-7/IL-24 protein secreted from Ad.5/3-mda-7-infected RCCs induced MDA-7/IL-24 expression and promoted apoptosis in uninfected "bystander" RCCs. MDA-7/IL-24 killed both infected and bystander RCCs via CD95 activation. Knockdown of intracellular MDA-7/IL-24 in uninfected RCCs blocked the lethal effects of conditioned media. Infection of RCC tumors in one flank, with Ad.5/3-mda-7, suppressed growth of infected tumors and reduced the growth rate of uninfected tumors implanted on the opposite flank. The toxicity of the serotype 5/3 recombinant adenovirus to express MDA-7/IL-24 was enhanced by combined molecular or small molecule inhibition of MEK1/2 and PI3K; inhibition of mTOR, PI3K and MEK1/2; or use of the multi-kinase inhibitor sorafenib. In RCCs, combined inhibition of cytoprotective cell signaling pathways enhanced the MDA-7/IL-24-induction of CD95 activation, with greater mitochondrial dysfunction due to loss of MCL-1 and BCL-XL expression, and tumor cell death. Treatment of RCC tumors in vivo with sorafenib also enhanced Ad.5/3-mda-7 toxicity and prolonged animal survival. Future combinations of these approaches hold promise for developing a more effective therapy for kidney cancer.

[1]  P. Fisher,et al.  Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. , 2010, Cancer research.

[2]  P. Fisher,et al.  Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  P. Karakiewicz,et al.  Treatment of metastatic renal cell carcinoma , 2010, Nature Reviews Urology.

[4]  P. Fisher,et al.  OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins , 2010, Cancer biology & therapy.

[5]  P. Fisher,et al.  Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells , 2010, The Prostate.

[6]  Z. Su,et al.  Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells , 2010, Cancer Gene Therapy.

[7]  P. Fisher,et al.  PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. , 2010, Cancer research.

[8]  P. Fisher,et al.  Cisplatin Enhances Protein Kinase R-Like Endoplasmic Reticulum Kinase- and CD95-Dependent Melanoma Differentiation-Associated Gene-7/Interleukin-24–Induced Killing in Ovarian Carcinoma Cells , 2010, Molecular Pharmacology.

[9]  P. Kellokumpu-Lehtinen,et al.  Prognostic factors and long-term survival in renal cell cancer patients , 2009, Scandinavian journal of urology and nephrology.

[10]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Fisher,et al.  MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism , 2009, Molecular Cancer Therapeutics.

[12]  P. Fisher,et al.  Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24 , 2009, Cancer biology & therapy.

[13]  P. Fisher,et al.  Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation , 2008, Cancer biology & therapy.

[14]  P. Fisher,et al.  Multiple Cyclin Kinase Inhibitors Promote Bile Acid-induced Apoptosis and Autophagy in Primary Hepatocytes via p53-CD95-dependent Signaling* , 2008, Journal of Biological Chemistry.

[15]  P. Fisher,et al.  MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors , 2008, Cancer biology & therapy.

[16]  P. Fisher,et al.  Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells , 2008, Molecular Cancer Therapeutics.

[17]  P. Fisher,et al.  Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling , 2008, Molecular Cancer Therapeutics.

[18]  S. Inoue,et al.  mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). , 2007, International journal of oncology.

[19]  P. Fisher,et al.  Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. , 2007, Toxicology and applied pharmacology.

[20]  Nanxin Li,et al.  B-Raf kinase inhibitors for cancer treatment. , 2007, Current opinion in investigational drugs.

[21]  K. Flaherty.  Sorafenib: delivering a targeted drug to the right targets , 2007, Expert review of anticancer therapy.

[22]  P. Fisher,et al.  mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. , 2006, Pharmacology & therapeutics.

[23]  P. Fisher,et al.  BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis. , 2006, Cancer research.

[24]  Z. Su,et al.  Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2 , 2006, Oncogene.

[25]  J. Gollob.  Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. , 2005, Clinical genitourinary cancer.

[26]  Dirk Strumberg,et al.  Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. , 2005, Drugs of today.

[27]  R. Ramesh,et al.  mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  Yuan Zhang,et al.  Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  P. Fisher,et al.  Mechanistic aspects of mda-7/IL-24 cancer cell selectivity analysed via a bacterial fusion protein , 2004, Oncogene.

[30]  P. Fisher,et al.  MDA-7 regulates cell growth and radiosensitivity in vitro of primary (Non-Established) human glioma cells , 2004, Cancer biology & therapy.

[31]  C. D. Krause,et al.  Interleukin-10 and related cytokines and receptors. , 2004, Annual review of immunology.

[32]  K. Hunt,et al.  MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  W. Linehan,et al.  MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity. , 2003, Molecular cancer therapeutics.

[34]  K. Madden,et al.  Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes , 2002, The Journal of Biological Chemistry.

[35]  P. Fisher,et al.  mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Retter,et al.  The Protein Product of the Tumor Suppressor Gene, Melanoma Differentiation-Associated Gene 7, Exhibits Immunostimulatory Activity and Is Designated IL-241 , 2002, The Journal of Immunology.

[37]  L. Broemeling,et al.  Loss of MDA-7 expression with progression of melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Fisher,et al.  The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells , 2002, Oncogene.

[39]  S. Pestka,et al.  Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties , 2001, Oncogene.

[40]  A. Sahin,et al.  Down‐regulated melanoma differentiation associated gene (mda‐7) expression in human melanomas , 2001, International journal of cancer.

[41]  Z. Su,et al.  A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Z. Su,et al.  The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Z. Su,et al.  Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. , 1995, Oncogene.

[44]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.